Syndax Pharmaceuticals (NASDAQ:SNDX) is up 21.6% after hours following some early data on its menin-inhibitor leukemia drug SNDX-5613.
“Within months of initiating the Phase 1/2
AUGMENT-101 trial, we are excited to present to the cancer research
community the first clinical evidence that disrupting the interaction
between menin and MLL1 with our potent and selective inhibitor,
SNDX-5613, can induce response in patients with genetically-defined
acute leukemias,” says CEO Dr. Briggs Morrison.
Clinical activity was achieved quickly after a
single 28-day cycle, he says, adding that more findings will come in the
fourth quarter.
SNDX-5613 was recently granted FDA Orphan Drug
Designation for the treatment of adult and pediatric acute myeloid
leukemia, the company says.
https://seekingalpha.com/news/3565030-syndaxplus-21_6-after-early-leukemia-drug-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.